Farnesyltransferase inhibitor effects on prostate tumor micro-environment and radiation survival

The Prostate
Yuquan ShiEric J Bernhard

Abstract

Ras activation by mutation, overexpression, or receptor signaling can increase tumor cell survival after irradiation. We examined whether inhibiting Ras activity with farnesyltransferase inhibitors (FTI) altered the radiosensitivity and tumor micro-environment in prostate tumors. Treatment with FTIs L-744,832 or FTI-277 reduced clonogenic survival of prostate tumor cells expressing oncogenic H-ras after irradiation. PI3-kinase/Akt and MAPK signaling pathways were downregulated by FTIs in these cells. FTI treatment reduced tumor hypoxia and also reduced MMP-9 expression in tumors with activated mutant H-ras. FTI treatment did not, however, increase apoptosis in irradiated intestine, demonstrating that acute radiation injury of this normal tissue was not enhanced by FTIs. FTIs can enhance the killing of prostate tumors with activated H-Ras. Together with the absence of increased acute toxicity to normal bowel, these results imply that FTI treatment should be further studied as a possible adjuvant to radiotherapy in the treatment of abdominal cancers with activated Ras signaling.

References

May 1, 1991·International Journal of Radiation Biology·M S MendoncaJ L Redpath
Apr 1, 1990·International Journal of Radiation Oncology, Biology, Physics·W G McKennaR J Muschel
Jan 1, 1994·International Journal of Radiation Biology·C S PottenA Faranda
Jul 15, 1994·International Journal of Cancer. Journal International Du Cancer·M WatanabeG N Stemmermann
May 10, 1994·Proceedings of the National Academy of Sciences of the United States of America·E J BernhardR J Muschel
Jan 1, 1994·International Journal of Radiation Oncology, Biology, Physics·S A LeibelW F Whitmore
Dec 20, 1996·Cancer Letters·C A CatesD N Crowell
Jan 3, 1997·Biochemical and Biophysical Research Communications·K F PirolloE H Chang
Aug 8, 1997·Biochimica Et Biophysica Acta·A D Cox, C J Der
Jul 17, 1998·Current Opinion in Chemical Biology·M H GelbJ S Sebolt-Leopold
Oct 21, 1998·Oncogene·P F Lebowitz, G C Prendergast
Nov 27, 1998·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·J DunstA Becker
Feb 5, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·W Z GuS C Ng
Jul 7, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R S KerbelJ Rak
May 12, 2001·Pathology Oncology Research : POR·A John, G Tuszynski
Mar 29, 2002·Medical Oncology·P VaupelM Hoeckel
Dec 24, 2002·Prostate Cancer and Prostatic Diseases·L Sepp-LorenzinoH I Scher

❮ Previous
Next ❯

Citations

May 8, 2008·Cancer Metastasis Reviews·Ramesh RenganStephen M Hahn
Oct 11, 2008·Nature Reviews. Cancer·Bradly G Wouters, Marianne Koritzinsky
Dec 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Elisabeth I HeathGlenn Liu
Jan 29, 2013·BMC Urology·Diego A PalaciosCharles J Rosser
Nov 29, 2016·Expert Opinion on Investigational Drugs·Claudio Festuccia
Dec 10, 2008·Artificial Cells, Blood Substitutes, and Immobilization Biotechnology·Minghua YuRuijuan Xiu
Mar 4, 2006·Molecular Cancer Research : MCR·Rob CairnsNicholas Denko

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis